Background: Pseudo-vitamin D deficiency rickets (PDDR; OMIM 264700) is a rare autosomal recessive disorder caused by mutations in the CYP27B1 gene, leading to an inability to synthesize 1␣,25-dihydroxyvitamin D 3 (calcitriol). The long-term (Ͼ1 yr) effects of calcitriol replacement treatment have not been reported.
pocalcemia and secondary hyperparathyroidism, with normal to elevated levels of 25-hydroxyvitamin D (25OH D) (4) .
To date, close to 100 patients with PDDR have been reported in the literature (5, 6) . Although identified in multiple ethnic groups, PDDR occurs at an unusually high frequency in the French Canadian population of some areas of Québec due to a founder effect (7) .
Many mutations in the CYP27B1 gene have been identified, including missense mutations, deletions, duplications, and splice mutations (5, 6) . The two most frequently observed mutations are a deletion of guanine at nucleotide 958 (g.958delG) in exon 2, commonly found in French Canadian patients, and a 7-bp duplication in exon 8, which arose independently in several populations (5) . The g.958delG mutation is predicted to result in a frame shift leading to a premature stop codon (8) . Most mutations associated with PDDR lead to a total loss of 1␣-OHase activity when expressed in vitro (8) .
Historically patients with PDDR were treated with high doses of vitamin D (20,000 -100,000 IU/d), in an attempt to overcome 1␣-OHase deficiency (9) . However, after 1,25(OH) 2 D 3 (calcitriol) became commercially available in 1973, the treatment of choice for PDDR patients has been replacement therapy with calcitriol (10 -12) . In a mouse model of PDDR, this treatment cures rickets and osteomalacia and restores the biomechanical properties of bones (13) . In short-term human studies, calcitriol rapidly corrected hypocalcemia, eliminated secondary hyperparathyroidism, and healed rickets (11) .
Available reports on the effect of calcitriol treatment of PDDR included less than 10 patients and had follow-up periods of less than 1 yr. The long-term outcome of calcitriol treatment in patients with PDDR has not been documented. In the present study, we present the results of 39 PDDR patients who received calcitriol for a period of 2.0 -26 yr.
Patients and Methods

Patient population
The study comprises all 31 patients with a diagnosis of PDDR who were followed up at the Shriners Hospital for Children in Montreal as well as eight patients who were followed up at Sainte Justine Hospital (Montréal, Québec) between 1977 and 2010. The data of these 39 patients (20 females, 19 males) were obtained by retrospective chart review. The total duration of follow-up ranged from 2.0 to 33 yr (median 19 yr).
The diagnosis of PDDR was based on the presence of clinical and radiological signs of rickets, hypocalcemia with secondary hyperparathyroidism, and low circulating levels of 1,25(OH) 2 D with normal to elevated levels of 25OH D. Sequence analyses of the CYP27B1 gene were performed in 27 individuals and identified mutations in each patient. The remaining 12 patients were not interested in genetic analysis.
For the purpose of the present analysis, two overlapping patient groups were distinguished. The pediatric group consisted of patients in whom data were available at the time of diagnosis in early childhood and during the first 2 yr of treatment with calcitriol. This pediatric group comprised 21 patients (seven females, 14 males). The adult group consisted of the 25 patients (14 females, 11 males) who at last follow-up were at final height.
At the time of the investigations presented here, all patients in the adult group had received calcitriol for 3.5-26.2 yr (median 13.8 yr). Seven of these patients had exclusively been treated with calcitriol from infancy to adulthood (adult group 1). Eighteen older patients had initially been treated with high doses of vitamin D (median dose 50,000 IU/d, range 5,000 -100,000 IU/d) but subsequently received calcitriol after calcitriol had become available in Canada. In four of these patients, calcitriol was started before they had undergone the pubertal growth spurt (adult group 2), and in 14 patients calcitriol was commenced after the pubertal growth spurt (adult group 3).
The study was approved by the Shriners and Sainte-Justine Hospital Institutional Review Boards. Informed consent was obtained from the legal guardians and/or patients.
Follow-up
After starting calcitriol treatment in newly diagnosed children, serum levels of calcium, phosphate, alkaline phosphatase, and PTH, as well as urinary calcium excretion, were evaluated once per month for the first 3 months. Thereafter children were seen every 4 months as long as growth continued. After the growth period, follow-up visits occurred every 6 months. Height and weight measurements were obtained at each visit and were converted to age-and sex-specific z-scores on the basis of reference data published by the Centers for Disease Control and Prevention (14) . Renal ultrasound and ophthalmologic examinations were performed every 2 yr to assess for the presence of nephrocalcinosis and corneal calcium deposits. During pregnancy, serum levels of calcium, phosphate, alkaline phosphatase, and PTH as well as urinary calcium excretion were evaluated once every 2 months during the first two trimesters and once per month during the third trimester.
Biochemical measurements
Serum total calcium, phosphate, and alkaline phosphatase were measured using colorimetric methods (Monarch; Instrumentation Laboratories Inc., Lexington, MA). Initially, serum PTH concentration (fragment 39 -84) was determined by RIA (15 
Dual-energy x-ray absorptiometry
Dual-energy x-ray absorptiometry was performed in the anterior-posterior direction at the lumbar spine (L1-L4) using a Hologic QDR 2000W or 4500 device (Hologic Inc., Waltham, MA). Areal bone mineral density (BMD) results of children were converted to age-and sex-specific z-scores using Canadian ref-erence data (16, 17) . For adults, reference data provided by the manufacturer were used. An estimate of three-dimensional BMD (volumetric BMD, unit milligrams per cubic centimeter) was derived as described by Carter et al. (18) .
Sequence analysis of the CYP27B1 gene
Total genomic DNA was isolated from peripheral blood using the QIAamp DNA blood midi kit (QIAGEN Inc., Mississauga, Ontario, Canada). The coding regions of the CYP27B1 gene, including the exon-intron boundaries, were amplified by PCR using primers previously described (8) . The sequencing reaction was performed using a BigDye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA). The nucleotide sequence was determined using an Applied Biosystems 3100 DNA sequencer.
Sequence traces were aligned with the GenBank reference sequences of the CYP27B1 genomic DNA (AF027152). Mutations were numbered following the convention (http://www.hgvs.org/mutnomen/recs.html), which starts with the translation initiator methionine as amino acid ϩ1, and the A of the ATG codon as nucleotide ϩ1.
Statistical analysis
Raw results were transformed to age-and sex-specific z-scores from the average result in the reference population using the published reference data cited in the description of measurement techniques. The expected mean result of these transformed values in a healthy population is 0. The significance of the difference from 0 was calculated by the one-sample t test.
Differences between the groups were tested for significance using the Mann-Whitney U test for pairwise group comparisons and Kruskal-Wallis test for comparisons between more than two groups. Bonferroni's adjustment was used to adjust for multiple testing. Wilcoxon test was used to analyze changes during treatment. All tests were two tailed and throughout the study P Ͻ 0.05 was considered significant. These calculations were performed using the SPSS software, version 11.5 for Windows (SPSS Inc., Chicago, IL).
Results
Mutations in the CYP27B1 gene
Homozygous or compound heterozygous mutations were found in all 27 patients who had sequence analysis of the CYP27B1 gene (Supplemental Table 1 ). Eighteen patients were homozygous for the g.958delG frame shift in exon 2. One patient was homozygous for the g.3392-3398 duplication in exon 8. All other patients were compound heterozygous. Among these, four patients were compound heterozygous for the g.958delG frame shift and the g.3392-3398 duplication. Compared with the mutations previously published, five new mutations were found (g.913GϾC, g.1609delC, g.3311AϾG, g.3430GϾA, g.3902GϾC). The clinical presentation of the four patients with missense mutations (patients 5, 12, 16, and 19) was indistinguishable from that of the patients with frame shift mutations.
Pretreatment results in young children
One baby (patient 1, Table 1 ) was assessed at the age of 1 month in the absence of any symptoms because a sibling was affected with PDDR. This infant had a height of 56.7 cm (z-score ϩ0.8), a weight of 4.95 kg (z-score ϩ0.9), and there were no clinical or radiological signs of rickets. Normal results were found for serum levels of total calcium The other 20 patients in the pediatric group were symptomatic at the time of the first evaluation. The majority of patients presented with neurological signs, such as delayed gross motor development and hypotonia (n ϭ 14) or hypocalcemic seizures (n ϭ 3) ( Table 1) . Clinical and radiological signs of active rickets were found in all of these 20 children. Twelve of the 17 patients (70%) with a documented pretreatment height had short stature (height zscore at or below Ϫ2.0), and only two children had a height z-score above Ϫ1.
The pretreatment median height and weight z-scores of the 20 symptomatic children were significantly below the average values expected for healthy children ( Table 2) . Evaluation of pretreatment growth curves, available in 13 children, revealed that growth trajectories started to cross the percentile curves in a downward direction at a median age of 9 months (range 5-21 months). Age at presentation was negatively associated with height z-score (R 2 ϭ 0.48, P ϭ 0.002) (Fig. 1) .
At the time of the pretreatment evaluation, all 20 of these children had hypocalcemia and high alkaline phosphatase levels. Serum phosphorus levels, documented in 14 children, were variable, with low values (Ͻ1.23 mmol/ liter) in five children. Baseline PTH levels, documented in nine children, were very high (on average 8-fold above the upper limit of the assay specific reference range; range 2.8-to 17-fold), indicating secondary hyperparathyroidism. In 12 patients, baseline serum levels of 1,25(OH) 2 D were not available because they had initially been diagnosed at another hospital. Baseline lumbar spine areal BMD, documented in five children, was very low with a median zscore of Ϫ5.2 (range Ϫ6.4 to Ϫ3.2).
Evolution during the first 2 yr of calcitriol treatment in newly diagnosed children
Calcitriol solution was started on an outpatient basis at a dose of 1.0 g/d, given in two doses of 0.5 g. Subsequently the calcitriol dose was modified according to the results of biochemical analyses. The aims of the treatment were to achieve normocalcemia, to maintain PTH levels within normal limits, and to avoid hypercalciuria. After 3 months of treatment, the median daily calcitriol dose was 0.50 g/d (range 0.2-1.0 g). Median daily calcitriol doses were 0.25 g after 1 yr (range 0.1-1.0 g) and 0.25 g after 2 yr (range 0.1-0.5 g) of treatment.
Treatment with calcitriol resulted in the normalization of serum levels of calcium, phosphate, alkaline phosphatase, and PTH within 3 months. In the five patients with available bone densitometry data, lumbar spine areal BMD z-scores increased markedly in the first 3 months of treatment and then remained stable (Fig. 2) . In the 12 patients with a documented pretreatment height, height z-scores increased more gradually.
The onset of walking had been documented in eight children who at the time of referral (median age of 18 months, range 12-24) had never walked. In these children, the median duration for walking after starting calcitriol treatment was 3 months (range 2-6 months). 
Evolution of calcitriol doses from childhood to adulthood
The evolution of calcitriol doses from 4 to 17 yr of age was available in seven patients (one female, six males). After the initial adjustments described in the previous section, calcitriol doses were increased as needed to maintain PTH levels within normal limits. In the period from 4 to 9 yr of age, the median daily calcitriol dose increased from 0.25 to 0.50 g. From 11 to 15 yr of age, median calcitriol doses increased from 0.50 to 0.75 g/d.
Long-term outcome in adults
During calcitriol treatment, 25OH D serum levels were normal in all 17 adult patients with available data (median of 101 nmol/liter, range 50 -145 nmol/liter), and 1,25(OH) 2 D levels were normal in 12 of 15 adult patients (median 101 pmol/liter, range 72-163 pmol/ liter; normal range 65-134 pmol/liter) and slightly low in the three remaining patients (57, 58, and 61 pmol/liter).
The height of adult patients varied with treatment history and was significantly associated with the age at which calcitriol treatment was started (R 2 ϭ 0.57, P Ͻ 0.0001) (Fig. 3) . Patients who received calcitriol only after the pubertal growth spurt (group 3) were significantly shorter than patients who were treated with calcitriol since infancy (group 1) or patients who initially were treated with high doses of vitamin D but then started calcitriol treatment before the pubertal growth spurt (group 2, Table 3 ). In group 3, height was significantly lower than in the general population (P Ͻ 0.001), whereas average height in the other two groups was as expected for a healthy population. Lumbar spine areal BMD z-scores were normal in all adult patients, regardless of treatment history.
There was no evidence of increased bone fragility. Fracture history at the time of the last follow-up (available in 22 patients; median age 45.4 yr; range 18.4 -063.9 yr) revealed that three patients had sustained fractures (wrist, humerus, and metatarsal bone) while receiving calcitriol, but these fractures occurred after significant trauma and healed normally.
Severe enamel hypoplasia was documented in 13 of 16 adult patients of groups 2 and 3 (81%), necessitating dental extraction in 10 patients. In group 1, two of five (40%) patients had some enamel hypoplasia but had not required dental extraction.
Screening for potential adverse events of hypercalcemia revealed that one patient (4% of the study population) had mild corneal calcium deposits, and four patients (16%) had mild nephrocalcinosis on renal ultrasound. The median urinary calcium to creatinine ratio of the 236 urine tests that were performed in the patients with nephrocalcinosis (0.37 mmol/mmol) was similar to the median urinary calcium to creatinine ratio of the 1068 urine test that were performed in the patients without nephrocalcinosis (0.34 mmol/mmol).
Except for moderate arterial hypertension in two patients, there was no history of other serious health disorders in the group of adult patients.
Pregnancies in women with PDDR
Nine women with PDDR had a total of 19 documented pregnancies (Supplemental Table 2 ). During pregnancy, doses of calcitriol were adjusted according to the results of biochemical analyses (obtained every 4 wk) to maintain serum calcium levels within normal limits. Thus, calcitriol doses were increased during 12 of the 19 pregnancies. After delivery, calcitriol treatment was continued at prepregnancy doses. All these pregnancies were without complications. In particular, there was no case of intrauterine growth retardation and all newborns were normocalcemic at birth. 
Discussion
Here we describe the largest cohort of PDDR patients that has been reported until now. Most patients were initially brought to medical attention as infants with neurological symptoms, especially delayed walking. This may be related to the importance of vitamin D for muscle strength and highlights the fact that the diagnosis of rickets should be considered in infants with developmental delay (19) .
The distribution of presenting signs and symptoms seems to differ somewhat between PDDR and vitamin D deficiency rickets. Compared with the patients with vitamin D deficiency rickets reported by Ladhani et al. (20) , our patients with PDDR presented more frequently with short stature (70% in patients with PDDR vs. 3% in patients with vitamin D deficiency rickets), motor delay (70 vs. 3%), and clinical signs of rickets (100 vs. 70%). In contrast, infants with PDDR seem to present with seizures less frequently than patients with vitamin D deficiency rickets (15 vs. 25%).
Contrary to patients with severe vitamin D deficiency who can present within the first 6 months of age (20) , none of the PDDR patients described here were symptomatic before the age of 6 months. This is unlikely to be due to the presence of maternal 1,25(OH) 2 D 3 in the circulation of the infant because 1,25(OH) 2 D 3 does not cross the fetoplacental barrier (21) . Indeed, the infant who was diagnosed with PDDR at the age of 1 month had a serum low level of 1,25(OH) 2 D and a positive CYP27B1 sequencing result but did not have any clinical or radiological signs of rickets. This indicates that 1,25(OH) 2 D is not critical for mineral ion homeostasis and growth plate mineralization in the first months of life. Similarly, 1␣-OHase deficient mice appear normal from birth until weaning (22) .
After the start of calcitriol treatment, biochemical parameters quickly normalized, as previously described (11) . A new observation is that lumbar spine areal BMD also normalized within 3 months. A similar increase in areal BMD has been reported in children and adults who were treated for vitamin D deficiency (23) . The rapidity of the increase in areal BMD suggests that the treatment initially led to the mineralization of preexisting unmineralized osteoid rather than the production of new bone matrix. The height deficit persisted longer than the low areal BMD, but after 2 yr of calcitriol treatment, height was also normalized and remained so until adulthood. It is noteworthy that even those patients who received calcitriol only after puberty had normal areal BMD, even though their average height was low. It thus appears that having low levels of 1,25(OH) 2 D 3 during childhood is compatible with achieving a normal peak bone mass.
Although essentially expressed throughout the nephron, 1␣-OHase activity is also detected in chondrocytes and osteoblasts. It has been hypothesized that local production of 1,25(OH) 2 D 3 could play an important autocrine and paracrine role in endochondral ossification and chondrocyte development (24) . Indeed, observations in mice suggest that chondrocyte-specific inactivation of Cyp27b1 or the vitamin D receptor leads to abnormalities in endochondral bone development (25, 26) . These mouse data are somewhat at odds with the present observations in humans. It can be assumed that in our patients both the systemic and the local production of 1,25(OH) 2 D were disrupted due to CYP27B1 mutations but systemic treat- ment with calcitriol nevertheless led to a normal growth rate and normal areal BMD. Despite careful follow-up over many years, no skeletal abnormalities were observed in patients with PDDR who had received calcitriol since infancy. It thus seems that in humans local production of 1,25(OH) 2 D in bone or growth cartilage cells is not critically important for skeletal development and homeostasis, even though subclinical growth plate abnormalities could evidently not be excluded in our patients. Female mice that are deficient in 1␣-OHase (and that do not receive calcitriol) have uterine hypoplasia and absent corpora lutea and thus are infertile (22) . The 1␣-OHase gene is expressed in human endometrial stromal cells with a significant increase in early pregnancy, suggesting a potential role of local production of 1,25(OH) 2 D in pregnancy establishment or maintenance (27) . In our study, female pubertal development seemed to be normal, and 19 pregnancies were documented in nine of the 13 women who were above 20 yr of age. It therefore appears that local production of 1,25(OH) 2 D in female reproductive organs is not critical for fertility because systemic supplementation was sufficient to achieve fertility.
The pregnancies that occurred in the women of the present cohort were without any complications, and all newborns were normocalcemic at birth. This indicates that the approach of determining calcium levels every 4 wk during pregnancy and to increase calcitriol doses as needed to maintain normocalcemia was a successful strategy.
Treatment with calcitriol was well tolerated in our population, with a low rate of adverse events that might be attributable to hypercalcemia. In particular, mild nephrocalcinosis was observed in 16% of the patients described here, whereas about 80% of patients with hypophosphatemic rickets receiving calcitriol have been reported to develop nephrocalcinosis (28) . The risk of nephrocalcinosis may be lower in patients with PDDR because phosphate excretion is normal, whereas phosphate excretion is elevated hypophosphatemic rickets.
Conclusion
Treatment with calcitriol started in infancy results in short-and long-term correction of all clinical, biochemical, and radiological abnormalities related to PDDR, without serious adverse events. 
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